References
- Hotta K, Kiura K, Takigawa N, Fujiwara Y, Tabata M, Ueoka H, et al Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer ( in press).
- Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, et al Effect of gefitinib ('Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:255–61.
- Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, et al. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 2005; 44: 717–22
- Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, et al Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol ( in press).
- Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience. Ann Oncol 2005; 16: 1817–23
- Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, Fujiwara Y, et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2007; 2: 632–7
- Hotta K, Tabata M, Kiura K, Kozuki T, Hisamoto A, Katayama H, et al. Gefitinib induces premature senescence in non-small-cell lung cancer cells with or without EGFR gene mutation. Oncol Rep 2007; 17: 313–7
- Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–46
- Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go, et al Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance. Ann Oncol 2004;15:173–4.
- Massacesi C, Rocchi MB, Marcucci F, Pilone A, Galeazzi M, Bonsignori M. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Int J Biol Markers 2003; 18: 295–300
- Hotta K, Kiura K, Tabata M, Takigawa N, Fujiwara Y, Umemura S, et al. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. Anticancer Res 2007; 27: 1737–41